Clinical Trials of Botulinum Toxin in Adult Spasticity

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 148-158

  Elia, Antonio E ^a   Filippini, Graziella ^a   Albanese, Alberto ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882923121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00012-3     Document Type: Chapter

References (53)

1. Lance JW The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology 1980, 30:1303-1313.
2. Sheean GL Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?. Curr Opin Neurol 2001, 14:771-776.
3. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347:395-400.
4. O'Dwyer NJ, Ada L, Neilson PD Spasticity and muscle contracture following stroke. Brain 1996, 119:1737-1749.
5. Woldag H, Hummelsheim H Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients?. Eur Neurol 2003, 50:165-171.
6. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002, 83:1349-1354.
7. Ashworth B Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964, 192:540-542.
8. Bohannon RW, Smith MB Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-207.
9. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999, 13:373-383.
10. Pandyan AD, Van Wijck FM, Stark S, Vuadens P, Johnson GR, Barnes MP The construct validity of a spasticity measurement device for clinical practice: an alternative to the Ashworth scales. Disabil Rehabil 2006, 28:579-585.
11. Platz T, Eickhof C, Nuyens G, Vuadens P Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005, 27:7-18.
12. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989, 320:1517-1521.
13. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000, 707-712.
14. Mutlu A, Livanelioglu A, Gunel MK Reliability of goniometric measurements in children with spastic cerebral palsy. Med Sci Monit 2007, 13:CR323-CR329.
15. Chung SG, Van Rey E, Bai Z, Roth EJ, Zhang LQ Biomechanic changes in passive properties of hemiplegic ankles with spastic hypertonia. Arch Phys Med Rehabil 2004, 85:1638-1646.
16. de Jong LD, Nieuwboer A, Aufdemkampe G The hemiplegic arm: interrater reliability and concurrent validity of passive range of motion measurements. Disabil Rehabil 2007, 29:1442-1448.
17. Biering-Sorensen F, Nielsen JB, Klinge K Spasticity-assessment: a review. Spinal Cord 2006, 44:708-722.
18. Cohen ME, Marino RJ The tools of disability outcomes research functional status measures. Arch Phys Med Rehabil 2000, 81(suppl 2):S21-S29.
19. Hinderer SR, Gupta S Functional outcome measures to assess interventions for spasticity. Arch Phys Med Rehabil 1996, 77:1083-1089.
20. Wade DT, Collin C The Barthel ADL Index: a standard measure of physical disability?. Int Disabil Stud 1988, 10:64-67.
21. Heller A, Wade DT, Wood VA, Sunderland A, Hewer RL, Ward E Arm function after stroke: measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry 1987, 50:714-719.
22. Lyle RC A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res 1981, 4:483-492.
23. Naumann M, Yakovleff A, Durif F A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002, 249:57-63.
24. Lincoln N, Leadbitter D Assessment of motor function in stroke patients. Physiotherapy 1979, 65:48-51.
25. Yelnik AP, Colle FM, Bonan IV, Vicaut E Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007, 78:845-848.
26. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310.
27. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004, 85:1063-1069.
28. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402-2406.
29. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001, 8:559-565.
30. Suputtitada A, Suwanwela NC The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005, 27:176-184.
31. Hesse S, Reiter F, Konrad M, Jahnke MT Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998, 12:381-388.
32. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000, 69:217-221.
33. Smith SJ, Ellis E, White S, Moore AP A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000, 14:5-13.
34. Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003, 15:289-300.
35. Kong KH, Neo JJ, Chua KS A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007, 21:28-35.
36. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996, 61:265-269.
37. Brashear A, McAfee AL, Kuhn ER, Fyffe J Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004, 85:705-709.
38. Kabus C, Hecht M, Japp G, Jost WH, Pohlau D, Stuckrad-Barre S, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol 2006, 253(suppl. 1):I26-I28.
39. Snow BJ, Tsui JK, Bhatt MH Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990, 28:512-515.
40. Grazko MA, Polo KB, Jabbari B Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995, 45:712-717.
41. Shakespeare DT, Boggild M, Young C Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003, (4):CD001332.
42. Ashworth NL, Satkunam LE, Deforge D Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2006, (1):CD004156.
43. Cioni M, Esquenazi A, Hirai B Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot. Am J Phys Med Rehabil 2006, 85:600-606.
44. Wasiak J, Hoare B, Wallen M Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004, (4):CD003469.
45. Naumann M, Jankovic J Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004, 20:981-990.
46. Turkel CC, Bowen B, Liu J, Brin MF Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006, 87:786-792.
47. Dressler D, Eleopra R Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 2006, 9:121-125.
48. Esquenazi A Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol 2006, 13(suppl 4):27-34.
49. Jankovic J, Schwartz K Botulinum toxin injections for cervical dystonia. Neurology 1990, 40:277-280.
50. Bentivoglio AR, Albanese A Botulinum toxin in motor disorders. Curr Opin Neurol 1999, 12:447-456.
51. Gracies JM Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001, 12:747-768.
52. Mayer NH, Esquenazi A Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am 2003, 14:855. , viii.
53. Mayer NH Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve 1997, 20(Suppl.6):S1-S13.